Coreline Soft (CEO Jin-Kook Kim), a medical AI specialized company, has recently achieved consecutive successes in major government-led AI healthcare projects.
Coreline Soft announced on the 9th that it has been finally selected for the Seoul Metropolitan Government’s 2025 Bio & Medical Technology Commercialization Support Program. This project, organized by the Seoul Metropolitan Government and the Seoul Business Agency, is an R&D support program aimed at elevating innovative technologies in the bio and medical fields to the stages of clinical application and commercialization. Recently, the company was also selected as the final implementing institution of the “AI-Based Healthcare System Digital Transformation Support Project,” through which it has successfully established the first-ever “4-in-1” chest AI diagnostic platform in a public medical center over two years with a total project value of KRW 23.2 billion, and succeeded in entering the public medical center network.
Through this support program, Seoul City provides backing across all stages from technology development to prototype production, testing and certification, and commercialization. In the selection process, Coreline Soft received high scores in △the possibility of solving the technical challenge of AI image processing specialized for low-dose CT △business feasibility guaranteed by expandability to multiple diseases such as lung cancer, cardiovascular disease, and COPD △the possibility of overseas expansion through global references already secured in Germany, the UK, Italy, and France. In particular, collaboration with Asan Medical Center holds significance as it combines Korea’s highest-level clinical data and research capabilities, thereby securing AI reliability verification and real-world applicability.
Accordingly, over the next two years, Coreline Soft will advance AI technologies for noise reduction and kernel conversion necessary for low-dose chest CT (LDCT) screening through joint R&D with Asan Medical Center. This research is expected to contribute to improving image quality in early lung cancer screening and increasing reading accuracy.
Coreline Soft is accelerating its medium- to long-term global strategy covering Korea, Europe, and the United States. In Korea, the company is realizing not only technological excellence but also social impact and sustainability, while in Europe, it is solidifying national-level infrastructure projects by participating in major countries’ lung cancer screening programs such as Germany and Italy. In the U.S. market, the company is diversifying its business by entering the insurance market and engaging in direct collaboration with local imaging centers.
CEO Jin-Kook Kim of Coreline Soft stated, “Based on joint research with Asan Medical Center, we will develop next-generation medical AI solutions that further enhance image quality and reading accuracy, and quickly disseminate them to domestic and international screening sites to establish ourselves as the global standard platform for early detection. As demand grows in Europe and the U.S. for multi-disease early screening and AI-based integrated diagnosis, we will generate achievements in both public healthcare and private insurance.”
2025.09.09
Contact us
General inquiries
Business Department
Overseas Business Department
Customer Service Team
IR-related inquiries
List